Abstract 111P
Background
In present time, neoadjuvant chemoradiotherapy for distal rectal cancer is part of clinical guidelines in Europe and the USA. According to the literature, there are no unified standards for upper rectal cancer.
Methods
The study included data from patients over 18 years old, with histologically proven adenocarcinoma with TNM stage T2-4aN0-2M0 and tumour location in the upper part of the rectum (10-15 sm). In the main group (A), preoperative chemoradiotherapy was performed: short-course radiotherapy (5x5 Gy), with capecitabine 2000 mg/m2 × 2 times for 14 days, followed by surgical treatment. In the control group (B) only surgical treatment was performed - partial or total mesorectumectomy.
Results
From January 2004 to December 2014, 226 (99.6%) underwent surgical treatment. The incidence of postoperative complications byClavien-Dindo scale was:group A - 17 (16.5%) and group B - 11 (8.9%). Local recurrences in group A occurred in 1 patient (1.2%), in group B - in 3 (2.5%) patients (p = 0.413). Distant metastases in group A developed in 10 (10.2%) patients, in group B -15 (12.6%) patients (p = 0.581). Overall survival was in group A - 90.6%, recurrence-free - 89.6%; in group B - 82.8% and 81.9%, respectively (p = 0.46). Multivariate analysis showed that the affected regional lymph nodes were the main predictor of poor prognosis (p = 0.001, OR = 0.094, CI = 0.035-0.250) and significantly reduced the 5-year disease-free survival rate (p = 0.001, OR = 4.213, CI = 2.010-8.830).
Conclusions
The results of the study showed that neoadjuvant chemoradiotherapy in comparison with the surgical method does not have an advantage for patients with upper rectum cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jasur Madyarov.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract